顺氯氨铂(Cis-dichlorodiammine-platinum,CDDP)简称顺铂(cisplatin),是治疗卵巢癌有显效的药物之一。文献表明,按常规经静脉途径给药,单一顺铂在作为第一线抗癌药时的有效率在67%左右;作为第二线药物时的有效率为30-50%。当顺铂和其他抗癌药联合应用时疗效更佳,有效率可达93%,其中显效43%,并可使晚期卵巢癌的生存时间平均达19个月。但是顺铂经静脉化疗后,卵巢癌的复发率仍占一 Cis-dichlorodiammine-platinum (CDDP), referred to as cisplatin, is one of the most effective drugs for the treatment of ovarian cancer. Literature shows that, according to conventional intravenous route, a single cisplatin in the first-line anti-cancer drugs, the effective rate of about 67%; as the second-line drugs, the effective rate of 30-50%. When cisplatin and other anticancer drugs combined with a better effect, the effective rate of up to 93%, of which 43% markedly, and can make the survival of advanced ovarian cancer average of 19 months. However, cisplatin by intravenous chemotherapy, the recurrence rate of ovarian cancer is still one